High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice

mAbs

Volumn 7, Issue 4, 2015, Pages 770-777

  Kelly, Ryan L ^a   Sun, Tingwan ^b   Jain, Tushar ^c   Caffry, Isabelle ^b   Yu, Yao ^b   Cao, Yuan ^b   Lynaugh, Heather ^b   Brown, Michael ^b   Vásquez, Maximiliano ^c   Dane Wittrup, K ^a   Xu, Yingda ^b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Protein Analytics Adimab   (United States)

^c NONE   (United States)

Author keywords

Clearance; Cross interaction; Developability; High throughput screening; Monoclonal antibody; Non specificity; PK; Self interaction; Stickiness

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ANIMAL; CROSS REACTION; IMMUNOLOGY; PROTEIN STABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; MICE; PROTEIN STABILITY;

EID: 84983684931     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1043503     Document Type: Article

References (28)

1. Jacobs SA, Wu S-J, Feng Y, Bethea D, O’Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res [Internet] 2010 [cited 2012 Dec 31]; 27: 65-71. Available from: http://www.ncbi.nlm.nih. gov/pubmed/19911257
2. Hotzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs [Internet] 2012 [cited 2013 Jan 24]; 4: 753-60. Available from: http://migrate.landesbio science.com/journals/mabs/article/22189/?show_full_ textDtrue
3. Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel [Internet] 2013 [cited 2014 Jan 21]; 26: 663-70. Available from: http://www.ncbi.nlm.nih. gov/pubmed/24046438
4. Nishi H, Miyajima M, Wakiyama N, Kubota K, Hasegawa J, Uchiyama S, Fukui K. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng 2011; 112: 326-32; PMID: 21783411; http://dx.doi.org/ 10.1016/j.jbiosc.2011.06.017
5. Sun T, Reid F, Liu Y, Cao Y, Estep P, Nauman C, Xu Y. High throughput detection of antibody self-interaction by bio-layer interferometry. MAbs [Internet] 2013; 5: 838-41. Available from: http://www.ncbi.nlm. nih.gov/pubmed/23995620
6. Liu Y, Caffry I, Wu J, Geng S, Jain T, Sun T, Reid F, Cao Y, Estrep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs [Internet] 2013 [cited 2014 Jan 21]; 6: 1-10. Available from: http://is.landesbioscience.com/jour nals/mabs/toc/volume/6/issue/2/
7. Geng SB, Cheung JK, Narasimhan C, Shameem M, Tessier PM. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci [Internet] 2014 [cited 2014 Sep 17]; 103: 3356-63. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/25209466
8. Jayaraman J, Wu J, Brunelle MC, Cruz AMM, Goldberg DS, Lobo B, Shah A, Tessier PM. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng [Internet] 2014 [cited 2014 Nov 5]; 111: 1513-20. Available from: http://www.ncbi.nlm. nih.gov/pubmed/25367343
9. Sule SV, Sukumar M, Weiss WF, Marcelino-Cruz AM, Sample T, Tessier PM. High-throughput analysis of concentration- dependent antibody self-association. Biophys J [Internet] 2011 [cited 2013 Jan 28]; 101: 1749-57. Available from: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artidD3183799&toolDpmcentrez& rendertypeDabstract
10. Sule SV, Dickinson CD, Lu J, Chow C-K, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm [Internet] 2013; 10: 1322-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23383873; PMID: 23383873
11. WHO. International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended International Nonproprietary Names list 65. WHO Drug Inf [Internet] 2011; 25: 65-77. Available from: http://www. who.int/medicines/publications/druginformation/ innlists/en/
12. Ames RS, Appelbaum ER, Chaiken IM, Cook RM, Gross MS, Holmes SD, McMillan LJ, Theisen TW. Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders. 1997; Available from: https:// www.google.com/patents/US5693323. VH is sequence ID 19 and VL is sequence ID 21.
13. WHO. International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended International Nonproprietary Names list 57. WHO Drug Inf 2007; 21: 53-83
14. Xiang H, Reyes AE, Eppler S, Kelley S, Damico-Beyer LA. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection. Cancer Chemother Pharmacol [Internet] 2013 [cited 2014 Feb 13]; 72: 405-15. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/23771513
15. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci [Internet] 2004 [cited 2014 Mar 26]; 93: 2645-68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15389672
16. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel [Internet] 2010 [cited 2014 Aug 29]; 23: 385-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20159773
17. Toutain PL, Bousquet-Mélou A. Plasma clearance. J Vet Pharmacol Ther [Internet] 2004; 27: 415-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15601437
18. Lin Y, Nguyen C, Mendoza J. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor…. Pharmacol … [Internet] 1999 [cited 2015 Jan 16]; 288: 371-8. Available from: http://jpet.aspetjournals.org/con tent/288/1/371.short
19. Junghans R, Anderson C. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci [Internet] 1996 [cited 2015 Jan 29]; 93: 5512-6. Available from: http://www.pnas.org/content/93/11/5512.short
20. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem [Internet] 2004 [cited 2015 Jan 29]; 279: 6213-6. Available from: http://www.ncbi.nlm. nih.gov/pubmed/14699147
21. Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem [Internet] 2006 [cited 2015 Jan 15]; 281: 23514-24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16793771
22. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol [Internet] 2010 [cited 2014 Dec 30]; 28: 157-9. Available from: http://www.pubmedcen tral.nih.gov/articlerender.fcgi?artidD2855492&toolD pmcentrez&rendertypeDabstract
23. Sievers SA, Scharf L, West AP, Bjorkman PJ. Antibody engineering for increased potency, breadth and halflife. Curr Opin HIV AIDS 2015; 10(3): 151-9. Available from: http://content.wkhealth.com/linkback/ openurl?sidDWKPTLP: landingpage&anD01222929-900000000-99538
24. Sigounas G, Harindranath N, Donadel G, Notkins AL. Half-life of polyreactive antibodies. J Clin Immunol 1994; 14: 134-40; PMID: 8195315; http://dx.doi.org/10.1007/BF01541346
25. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol [Internet] 2010 [cited 2014 Dec 1]; 184: 1968-76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20083659
26. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T, Al WET. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39: 1469-77; PMID: 21610128; http://dx.doi.org/10.1124/dmd.111.039453
27. Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A [Internet] 2014 [cited 2015 Jan 1]; 111: 18601-6. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/25512516
28. Estep P, Reid F, Nauman C, Liu Y, Sun T, Sun J, Xu Y. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs 2013; 5: 270-8; PMID: 23575269; http://dx.doi.org/10.4161/mabs.23049